Sample size in obesity trials: Patient perspective versus current practice

Medical Decision Making

Volumn 30, Issue 1, 2010, Pages 68-75

  Allison, David B ^a   Elobeid, Mai A ^a   Cope, Mark B ^a   Brock, David W ^a   Faith, Myles S ^b   Vander Veur, Stephanie ^a,c   Berkowitz, Robert ^b   Cutter, Gary ^a   McVie, Theresa ^a   Gadde, Kishore M ^d   Foster, Gary D ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Obesity; Randomized clinical trials; Risk; Weight loss

Indexed keywords

ADULT; AGED; ARTICLE; FEMALE; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; MALE; MIDDLE AGED; OBESITY; PATIENT; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SAMPLE SIZE; WEIGHT REDUCTION;

ADULT; AGED; DATA COLLECTION; FEMALE; HUMANS; INFORMED CONSENT; MALE; MIDDLE AGED; OBESITY; PATIENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SAMPLE SIZE; WEIGHT LOSS; YOUNG ADULT;

EID: 75949085305     PISSN: 0272989X     EISSN: 1552681X     Source Type: Journal    
DOI: 10.1177/0272989X09340583     Document Type: Article

References (30)

1. Fontaine KR, Redden DT, Wang C., Westfall AO, Allison DB Years of life lost due to obesity. JAMA. 2003 ; 289: 187-193.
2. Klein S., Burke LE, Bray GA, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism; American College of Cardiology Foundation. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2004 ; 110: 2952-2967.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM Prevalence of overweight and obesity in the United States, 1999-2004. JAMA. 2006 ; 295 (13). 1549-1555.
4. Ayyad C., Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev. 2000 ; 1 (2). 113-119.
5. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J., Rosenstock J. ; RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006 ; 295 (7). 761-775.
6. Chanoine JP, Hampl S., Jensen C., Boldrin M., Hauptman J. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005 ; 293 (23). 2873-2883.
7. Erondu N., Gantz I., Musser B., Suryawanshi S., Mallick M., Addy C., et al. Neuropeptide T5 antagonism does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab. 2006 ; 4: 275-282.
8. Ettinger MP, Littlejohn TW, Schwartz SL, et al. Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA. 2003 ; 289 (14). 1826-1832.
9. Gadde KM, Franciscy DM, Wagner HR II, Krishnan KR Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003 ; 289 (14). 1820-1825.
10. Wirth A., Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 2001 ; 286 (11). 1331-1339.
11. Heymsfield SB, Greenberg AS, Fujioka K., et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA. 1999 ; 282 (16). 1568-1575.
12. Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A., Greenfield D., Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. JAMA. 1998 ; 280 (18). 1596-1600.
13. US Food and Drug Administration. DVD recorded proceedings of Food and Drug Administration Center for Drug Evaluation and Research (CDER). Endocrinologic and Metabolic Drugs Advisory Committee Meeting, 8 September 2004.
14. US Food and Drug Administration. Guidance for industry developing products for weight management. 2007. Available from: URL: http://www.fda.gov/ cder/guidance/7544dft.pdf. Accessed 7 August 2008.
15. US Food and Drug Administration. NDA 21-888 Zimulti (rimonabant) tablets, 20 mg. 2007. Sanofi Aventis. Available from: URL: http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4306b1-fda-backgrounder.pdf. Accessed 7 August 2008.
16. US Food and Drug Administration. Minutes summary. 2007. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4306m1-final.pdf. Accessed 7 August 2008.
17. Katz R. Memorandum: briefing document for the July 10, 2008 advisory committee meeting to discuss antiepileptic drugs (AEDs) and suicidality. 12 June 2008. Available from: URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/ 2008-4372b1-01-FDA-Katz.pdf. Accessed 7 August 2008.
18. US Food and Drug Administration. (2008). Information for healthcare professionals: suicidality and antiepileptic drugs. http://www.fda.gov/cder/ drug/InfoSheets/HCP/antiepilepticsHCP.htm. Accessed 27 October 2008.
19. Curioni C., Andr C. Rimonabant for overweight and obesity. Cochrane Database Syst Rev. 2006 ;(4). CD006162.
20. Christensen R., Kristensen PK, Bartels EM, Bliddal H., Astrup A. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomized trials. Lancet. 2007 ; 370: 1706-1713.
21. Ioannides-Demos LL, Proietto J., McNeil JJ Pharmacotherapy for obesity. Drugs. 2005 ; 65 (10). 1391-1418.
22. Rosner BA Fundamentals of biostatistics. Belmont, CA: Thomson Brooks/Cole 2006.
23. Wee CC, Jones DB, Davis RB, Bourland AC, Hamel MB Understanding patients value of weight loss and expectations for bariatric surgery. Obes Surg. 2006 ; 16 (11). 496-500.
24. Debabrata M., Steven EN, Eric JT Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001 ; 286: 954-959.
25. Brennan A., Ara R., Sterz R., Matiba B., Bergemann R. Assessment of clinical and economic benefits of weight management with sibutramine in general practice in Germany. Eur J Health Econ. 2006 ; 7 (4). 276-284.
26. Muls E., Kolanowski J., Scheen A., Van Gaal L. ; ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord. 2001 ; 25 (11). 1713-1721.
27. McMillan-Price J., Petocz P., Atkinson F., et al. Comparison of 4 diets of varying glycemic load on weight loss and cardiovascular risk reduction in overweight and obese young adults: a randomized controlled trial. Arch Intern Med. 2006 ; 166 (14). 1466-1475.
28. OBrien BJ, Goeree R., Gafni A., et al. Assessing the value of a new pharmaceutical: a feasibility study of contingent valuation in managed care. Med Care. 1998 ; 36 (3). 370-384.
29. National Institutes of Health. Bariatric surgery for severe obesity. 2008. Publication No. 08-4006. Available from: URL: http://www.win.niddk.nih. gov/publications/gastric.htm.
30. Fabricatore AN, Wadden TA, Rohay JM, et al. Weight loss expectations and goals in a population sample of overweight and obese US adults. Obesity (Silver Spring). 2008 ; 16 (11). 2445-2450.